血管内皮生长因子在急性髓系白血病细胞中的表达

Expression of vascular endothelial growth factor in bone marrow cells of patients with acute myeloid leukemia

目的探讨血管内皮生长因子(VEGF)在成人急性髓系白血病(AML)的发生发展中的作用。方法采用逆转录PCR(RT-PCR)和酶联免疫吸附(ELISA)的方法研究50位AML病人及16位正常人骨髓细胞及血浆VEGF的表达。结果部分正常人和大多数AML病人的骨髓细胞及白血病细胞系均表达VEGF。AML病人骨髓细胞VEGF表达阳性率(82%)明显高于正常人(30.76%)及骨髓移植后的AML病人(41.76%)。难治型和非难治型AML病人血浆中VEGF浓度均显著高于正常人和AML骨髓移植后病人(P<0.01)。除正常人与骨髓移植后AML病人血浆中VEGF浓度比较无统计学差异外(P>0.05),另与其他两者之间均有显著性差异(P<0.01)。难治型和非难治型白血病病人骨髓细胞分泌的VEGF分别比正常人高11.0和7.3倍,且两者之间比较有显著性差异(P<0.01)。结论VEGF在AML病人中存在异常表达,在AML的发病机制中可能起一定的作用,且可能成为判断AML病人预后指标之一。

Objective To investigate the role of vascular endothelial growth factor (VEGF) in the pathogenesis and progression of acute myeloid leukemia (AML). Methods Reverse transcription-polymerase chain reaction (RT-PCR) was employed for VEGF mRNA detection. VEGF levels in the bone marrow cell cultural supernatant and plasma from normal subjects and AML patients were determined by enzyme-linked immunosorbent assay (ELISA). Results VEGF mRNA expression was present in most of the AML cell lines HL-60, K562 and Raji, but not in Jurkat cells. The expression rate of VEGF mRNA in the bone marrow cells from AML patients (82%) was higher than the rates in normal subjects (30.76%) and AML patients with autologous bone marrow transplantation (41.67%). Refractory and non-refractory AML patients had higher mean plasma VEGF levels than the normal donors and AML patients with transplantation did, without significant differences observed in the latter 2 groups. With also significant difference between them, refractory and non-refractory AML groups had respectively 11.0 and 7.3-fold higher VEGF levels in the culture supernatant than the normal donor group did. Conclusion The abnormality of VEGF expression may play an important role in the development of AML, and VEGF expression might be used as one of the indexes for prognostic assessment for AML patients.